Article: FDA adds black box to Xolair.(Warnings/Recalls)(Brief article)

FDA finalized a strong new label warning patients and doctors about a potentially deadly allergic reaction from Genentech's asthma drug Xolair.

The agency had proposed the so-called black box warning about anaphylaxis in February, but announced final wording of the label on July 2.

Xolair, given as an injection and known generically as omalizumab, is approved to treat adults and adolescents 12 years of age and older for moderate to severe asthma.

The previous label warned that ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!